Christian Angermayer

Christian Angermayer

Creator
0 followers

Entrepreneur/investor; atai Life Sciences; psychedelics and mental health

FDA Peptide Loosening Could Power Enhanced Games’ Public Debut
SocialMar 31, 2026

FDA Peptide Loosening Could Power Enhanced Games’ Public Debut

If the FDA follows through with lifting restrictions on several peptides, it could unlock a massive market opportunity in performance medicine. One of the most interesting candidates IMHO – with all the bias I have as one of the founders -...

By Christian Angermayer
Enhanced Games Could Deliver Credible Data for Peptide Legitimacy
SocialMar 31, 2026

Enhanced Games Could Deliver Credible Data for Peptide Legitimacy

Data, data, data... The @enhanced_games are so much more than just another sports event... "The peptide community has a credibility problem and an evidence problem. Millions of people use compounds backed by rodent studies and Reddit threads. The FDA is cracking...

By Christian Angermayer
Mental‑health Biotech Will Outgrow Disease‑focused Pharma
SocialMar 31, 2026

Mental‑health Biotech Will Outgrow Disease‑focused Pharma

Consumer biotech and pharma will ultimately be a much bigger business than sickness-focused biotech and pharma. And what people crave even more than being sexy is being happy. Hence, I believe #mentalhealth will be the largest subsector and companies like my @ataibeckley...

By Christian Angermayer
Pharma Rushes Into Psychedelics, M&A Activity Surges
SocialMar 27, 2026

Pharma Rushes Into Psychedelics, M&A Activity Surges

Pharma’s appetite for psychedelic therapies is rapidly accelerating, with M&A interest heating up across the sector.

By Christian Angermayer
The Killers to Headline Enhanced Games in Vegas
SocialMar 26, 2026

The Killers to Headline Enhanced Games in Vegas

I’ve been a fan for a long time, so I couldn’t be more excited that The Killers will headline our @enhanced_games on May 24th in Las Vegas. Televised globally. And this is just the beginning - many more entertainment announcements...

By Christian Angermayer
Analysts Underestimate ATAI's Expanding Psychedelic Market Potential
SocialMar 19, 2026

Analysts Underestimate ATAI's Expanding Psychedelic Market Potential

$ATAI is currently covered by 13 analysts, with price targets spanning $7 to $25. I believe though that the view of most investors and analysts on @ataibeckley appears largely anchored only to the initial lead indication and drug we are pursuing:...

By Christian Angermayer
ATAI: Top‑Positioned Psychedelic Biotech Leader
SocialMar 10, 2026

ATAI: Top‑Positioned Psychedelic Biotech Leader

Good moment to resurface this blog post explaining why I believe $ATAI is the best-positioned company in the psychedelic biotech sector 😉🚀

By Christian Angermayer